文献速递炎症性肠病

临床决策支持工具或有助于优化克罗恩病维多珠单抗治疗

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-12-22

研究基于GEMINI、GETAID和VICTORY三个独立数据集,评估临床决策支持工具(CDST)预测维多珠单抗(VDZ)暴露-疗效关系和疾病结局的效用。结果显示CDST分组与VDZ暴露、起效速度和疗效呈线性关系,并能预测手术风险。CDST可帮助识别最受益于缩短输注间隔和可能需要手术的患者。

要点

  • CDST分组与VDZ暴露、起效速度及疗效呈线性关系。
  • 低-中概率组较高概率组12个月手术风险增加约两倍(调整HR 2.06)。
  • 高概率患者未从缩短输注间隔中获益。

核心结论

  • CDST可准确预测VDZ的暴露-疗效关系和起效速度,并有助于识别受益于间隔缩短或需手术的患者。

研究设计与样本

  • 基于三个独立数据集(GEMINI、GETAID和VICTORY)的回顾性分析,按CDST定义的反应组(低、中、高概率)评估临床缓解率、VDZ暴露、起效速度、剂量优化反应和手术进展。

主要发现

  • 在GEMINI中,CDST定义的三组间VDZ暴露、起效速度和至52周的疗效呈线性关系(所有时间点P < 0.001)。
  • 在GETAID中,CDST预测第14周临床缓解的差异(AUC = 0.68)和起效速度的差异(P = 0.04)。
  • 高概率患者未从缩短输注间隔中获益;纳入接受第10周输注的低概率患者后,GETAID中高-中与低概率组间起效速度差异不再显著。
  • CDST预测低-中概率组较高概率组12个月VDZ治疗期间手术风险增加两倍(调整HR 2.06,95% CI 1.33-3.21)。

关键数值与推荐

  • CDST分组与第52周疗效线性关系P < 0.001(GEMINI)。
  • GETAID中CDST预测第14周临床缓解AUC = 0.68。
  • 起效速度差异P = 0.04(GETAID)。
  • 手术风险调整HR 2.06(95% CI 1.33-3.21)。

临床怎么用

  • CDST可用于基线预测VDZ暴露-疗效关系,辅助识别可能受益于缩短输注间隔的患者。
  • CDST可帮助识别VDZ治疗期间手术风险较高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn's disease. AIM: To assess the utility of this CDST for predicting exposure-efficacy and disease outcomes. METHODS: Using data from three independent datasets (GEMINI, GETAID and VICTORY), we assessed clinical remission rates and measured VDZ exposure, rapidity of onset of action, response to dose optimisation and progression to surgery by CDST-defined response groups (low, intermediate and high). RESULTS: A linear relationship existed between CDST-defined groups, measured VDZ exposure, rapidity of onset of action and efficacy in GEMINI through week 52 (P < 0.001 at all time points across three CDST-defined groups). In GETAID, CDST predicted differences in clinical remission at week 14 (AUC = 0.68) and rapidity of onset of action (P = 0.04) between probability groups. The high-probability patients did not benefit from shortening of infusion intervals, and differences in onset of action between the high-intermediate and low-probability groups within GETAID were no longer significant when including low-probability patients who received a week 10 infusion. CDST predicted a twofold increase in surgery risk over 12 months of VDZ therapy among low- to intermediate-probability vs high-probability patients (adjusted HR 2.06, 95% CI 1.33-3.21). CONCLUSIONS: We further extended the clinical utility of a previously validated VDZ CDST, which accurately predicts at baseline exposure-efficacy relationships and rapidity of onset of action and could be used to help identify patients who would most benefit from interval shortening and those most likely to require surgery while on active therapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Amiot A, Peyrin-Biroulet L, et al. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2019. PMID: 31867766. doi:10.1111/apt.15609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。